Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

The first FDA-approved nonprescription treatment for minor nosebleeds has hit the shelves of more than 5,400 CVS stores, according to an announcement by Mendon, N.Y.-based marketer Catalina Healthcare Feb. 1. NasalCEASE is a small sterile nasal packing made of a highly absorbent "natural 'bio-polymer' extracted from brown seaweed." It releases calcium to stop bleeding and "turns moist to prevent sticking to clots." FDA approval of the 510(k) device application was received in July 2004, but the product initially was only available through doctors and some independent pharmacies. Catalina Healthcare is a subsidiary of the French firm Les Laboratoires Brothier, and the product has been available over-the-counter in Europe for several years. A box of five individually wrapped sterile packs carries an SRP of $11.50. The firm plans to build consumer awareness through a national radio campaign slated to begin in April...

You may also be interested in...

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.

Unprecedented To Lawful: Regulatory Precedent Needed For Cannabinoids’ Use In Supplements?

“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts